Truvada News and Research

RSS

Vaginal ring used by most women for HIV prevention in open-label study

In an open-label study of women in southern and eastern Africa, a vaginal ring that is inserted once a month and slowly releases an antiviral drug was estimated to reduce the risk of HIV by 39%, according to statistical modeling.

24 Jul 2019

Tailored adherence strategies needed to engage young African women in consistent PrEP use

In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months.

24 Jul 2019

Even when HIV prevention drug is covered, other costs block treatment

Three years ago, Corey Walsh, who was in a relationship with a man who was HIV-positive, got a prescription for Truvada, a drug approved by the Food and Drug Administration to prevent infection with the virus that causes AIDS.

15 Jul 2019

Trump plan to beat HIV hits rough road in rural America

One of the goals President Donald Trump announced in his State of the Union address was to stop the spread of HIV in the U.S. within 10 years.

21 Feb 2019

MTN launches new study to empower teen girls with choices in HIV prevention

AIDS is already the leading cause of death among girls and young women in much of Africa, and matters could only get worse, given that for every day that passes, 1,000 more girls ages 15 to 24 are likely to become infected with HIV.

8 Feb 2019

Trump administration salutes parade of generic drug approvals, but hundreds aren’t for sale

The Trump administration has been trumpeting a huge increase in FDA generic drug approvals the past two years, the result of its actions to streamline a cumbersome process and combat anti-competitive practices.

7 Feb 2019

New simulation approach predicts efficacy of HIV-prophylaxis medications

A new mathematical simulation approach predicts the efficacy of pre- and post-exposure prophylaxis (PrEP) medications, which help prevent HIV infection. The framework, presented in PLOS Computational Biology by Sulav Duwal and Max von Kleist of Freie Universität Berlin and colleagues, could help streamline development of new PrEP treatments.

18 Jun 2018

PrEP campaign aims to block HIV infection and save lives in D.C.

A big part of Washington, D.C.’s plan to get its HIV rate down is to get more uninfected people on PrEP, a two-medicine combination pill that’s sold under the brand name Truvada.

13 Apr 2018

Use of HIV-prevention drug grows, but lags among non-whites

Eric Russell, 24, recently joined a health support group for young Latino and black gay men, where he learned about the HIV-prevention pill known as PrEP. He resisted the medication at first, convinced he didn't need it and fearful that taking it would stigmatize him.

15 Mar 2018

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

18 Oct 2017

HIV prevention drug to be trialed by Britain's NHS

After a High Court case, an HIV prevention drug is soon to be available on the NHS. NHS England has issued a statement saying that pre-exposure prophylaxis (PrEP) treatment for HIV shall be available to an initial 10,000 people for a trial period of three years.

3 Aug 2017

UTHealth participates in study to evaluate effectiveness of new injectable HIV medication

The HIV Prevention Trials Network, which includes McGovern Medical School at The University of Texas Health Science Center at Houston, has launched a study to evaluate whether a new injectable medication can work as well as an existing oral pill to safely protect against HIV among men who have sex with men (MSM) and transgender women (TGW) who have sex with men.

18 Apr 2017

CDC guidelines for PrEP use to prevent HIV transmission do not go far enough, UCLA study suggests

A new study from the UCLA Fielding School of Public Health suggests modifying federal health guidelines related to the use of pre-exposure prophylaxis to prevent HIV transmission because current standards could miss some people who should be on it.

12 Jan 2017

First large-scale clinical study of long-acting injectable HIV drug begins

The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today.

21 Dec 2016

Study explores men's perceptions of new HIV prevention treatment

The first study to explore United Kingdom men's perceptions of PrEP - a new HIV prevention treatment - has found that their opinions are negatively influenced by social stigma.

8 Dec 2016

Women report experimental vaginal ring for HIV prevention did not negatively affect sexual experience

Most women who used an experimental vaginal ring for HIV prevention report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear.

18 Oct 2016

New method estimates patient adherence to antiretroviral drugs

Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at CU Anschutz have developed a technique that estimates an HIVnegative patient's adherence to drugs prescribed to prevent HIV transmission during sex.

24 Aug 2016

Study provides new insights into real-world use of PrEP

Several studies presented today in an official press conference at the 21st International AIDS Conference in Durban provided new insights on the use of PrEP among a broad range of populations.

21 Jul 2016

Study confirms efficacy of PrEP in reducing risk of HIV infection in men who have sex with men

The last phase of ANRS IPERGAY has confirmed that "on-demand" pre-exposure prophylaxis (PrEP) is a highly effective method of reducing the risk of HIV infection in men who have sex with men and who report high-risk behavior.

20 Jul 2016

HOPE study seeks to understand safety of vaginal ring in protecting women against HIV

Women who took part in ASPIRE, a trial that found a vaginal ring containing an antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, will soon be offered the opportunity to use the ring as part of a new study called HOPE.

19 Jul 2016